Recent

% | $
Quotes you view appear here for quick access.

Yahoo! Inc. (YHOO) Message Board

whippersnapper65 226 posts  |  Last Activity: 14 minutes ago Member since: Jun 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Neuro-Oncology Ads

    by fludyspnea Feb 19, 2015 12:23 AM
    whippersnapper65 whippersnapper65 Feb 19, 2015 6:58 AM Flag

    This is SPLENDID news! I think it's a harbinger of early approval, much as Celldex being a platinum sponsor at the SNO meeting in November was a reliable indicator that the ReACT results would be extremely positive.

    Sentiment: Strong Buy

  • Reply to

    bye bye $20s - Kiss $21 today

    by aqnguyen Feb 17, 2015 9:32 AM
    whippersnapper65 whippersnapper65 Feb 17, 2015 2:39 PM Flag

    Institutions have purchased an unusually large number of shares in the last quarter. Even the largest holders increased their positions.

    Be assured of this: the institutions do not expect to make millions with their CLDX holdings; they expect to make hundreds of millions and even billions.

    Sentiment: Strong Buy

  • Reply to

    Final Rindo readout to be presented at ASCO

    by flogonuzim Feb 14, 2015 4:59 PM
    whippersnapper65 whippersnapper65 Feb 17, 2015 2:22 PM Flag

    You obviously know nothing about the company, nor about Rindo, nor about the relevant study, ReACT. The data have already been presented, and they are astoundingly, impressively, jaw-droppingly positive. The four remaining patients to form a complete database cannot turn such a positive study negative; in fact, the expectation is that the complete data set will be even more positive than what has already been presented.

    Sentiment: Strong Buy

  • Reply to

    SEC Filing - FMR added 1.380.000 shares

    by swissmilkcow Feb 13, 2015 10:22 AM
    whippersnapper65 whippersnapper65 Feb 13, 2015 10:28 AM Flag

    I continue to be amazed at how institutions have been accumulating while keeping the share price suppressed. The suppressed share price will not last much longer. All the major institutions know that Celldex is going to make them boatloads of money, which is why they are continuing to purchase shares. Institutional ownership must now be around 96%

    Sentiment: Strong Buy

  • Reply to

    CEO of Celldex on Rindo

    by raysfrom98 Feb 12, 2015 10:39 AM
    whippersnapper65 whippersnapper65 Feb 12, 2015 10:47 AM Flag

    All great news!

    Sentiment: Strong Buy

  • That was the position posted just before the excellent ReACT news, and it was the job that referenced preparing materials pertaining to the launch of Celldex's inaugural product, Rindopepimut.

    I'm pleased that the position appears to have been filled so quickly. Management is not wasting any time preparing for commercial launch of Rintega.

    Sentiment: Strong Buy

  • Reply to

    New 13-G Just Out

    by maximus06906 Feb 4, 2015 1:21 PM
    whippersnapper65 whippersnapper65 Feb 4, 2015 10:36 PM Flag

    With CLDX being manipulated so much with such volatility, while major institutions are reporting significantly increased accumulations of shares, with the institutional ownership percentage already extremely high and going higher, with the short percentage also extremely high and holding steady, yet the share price has barely moved during the accumulation after tremendously good news: all that combines as writing on the wall to portend an astonishingly meteoric rise in share price after the decisive good news about early approval is made public later this year.

    Sometime this year, hopefully soon, the share price games will end and CLDX will be revalued at a much, much higher multiple of today's absurdly low valuation.

    Sentiment: Strong Buy

  • Reply to

    briston myers - why is it such a

    by rxkell Jan 29, 2015 9:57 AM
    whippersnapper65 whippersnapper65 Jan 29, 2015 8:31 PM Flag

    Wow! I just checked the after-hours quote and news for ICPT. Shows you what will happen to CLDX when it receives breakthrough designation or commercial approval for Rintega.

    Makes you wonder why breakthrough designation hasn't been granted already, but it's not necessary for early approval. The excellent data are sufficient for that.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Jan 29, 2015 3:31 PM Flag

    Manipulation by IOs. If you're new to the stock, get used to it. The IOs want to own as many shares as they can without driving up the price. How do you think Blackrock managed to acquire that many more shares without causing the price to jump to the $30s overnight? They sell/buy/sell/buy/sell/buy and gradually they increase their holdings without running the price up much because they manage to trick retail holders into parting with their shares by triggering stop losses or scaring them with the volatility and sharp pullbacks.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Jan 29, 2015 2:47 PM Flag

    Yeah, they doubled their total holdings in CLDX. Very bullish sign. IO has to be over 95% now.

    Sentiment: Strong Buy

  • IOs want 99% of Celldex shares.

    Sentiment: Strong Buy

  • Reply to

    briston myers - why is it such a

    by rxkell Jan 29, 2015 9:57 AM
    whippersnapper65 whippersnapper65 Jan 29, 2015 1:26 PM Flag

    Varli has already demonstrated promising efficacy and safety as a monotherapy, notably a complete response in a Hodgkin lymphoma patient who had a death sentence because she had failed every prior therapy; varli was literally her last chance at life, and varli gave it to her! The biological mechanism of action for varli is well understood. The reason for the phase 1/2 combo trial is because it's the first trial of varli in combo with nivo, so proper dosages have to be determined (phase 1) before advancing to significant proof-of-concept (phase 2); then the large, statistically significant pivotal study (phase 3) can be conducted. However, if the combo demonstrates robust efficacy it is possible that the FDA could approve the combo of varli and nivo on the basis of phase 2 data. Nivo has already received accelerate approval on the basis of efficacy in a patient population with severe unmet need.

    Sentiment: Strong Buy

  • But Varli has had no history of adverse effects on patients to date.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Jan 29, 2015 10:31 AM Flag

    After all this time I should be used to the manipulation of CLDX, but it never ceases to annoy me. This stock ought to be trading in the mid-$30s minimum. Every good news release is used as an opportunity for manipulation rather than solid gains in market cap. The shorts seem to have an endless supply of shares available to sell.

    Sentiment: Strong Buy

  • Reply to

    Celldex now listing 22 open jobs

    by whippersnapper65 Jan 28, 2015 3:48 PM
    whippersnapper65 whippersnapper65 Jan 28, 2015 9:29 PM Flag

    Furthermore, Celldex is a fairly small company, having only about 130 employees. So to hire 22 more is a significant expansion of the total personnel.

    Sentiment: Strong Buy

  • The trials are now recruiting, so why hasn't the company publicized that development?

    Sentiment: Strong Buy

  • whippersnapper65 by whippersnapper65 Jan 28, 2015 3:48 PM Flag

    A new one today is: Director, Biopharmaceutical Process Development (Hampton, NJ or Needham, MA). Note how the job description mentions being responsible for "process scale up/optimization... for late state clinical development and subsequent commercialization of new biopharmaceutical products." Celldex is ramping up for commercialization.

    Job Description:

    This position will be responsible for managing drug substance and sterile drug product contract manufacturing operations, including tech transfer, process scale up/optimization, and process validation for late stage clinical development and subsequent commercialization of new biopharmaceutical products. This role requires a strong scientific background, strong project management skills, experience working with/for contract manufacturing organizations (CMOs), and demonstrated ability to develop biopharmaceuticals for clinical and commercial use. Strong interpersonal and communication skills are required.

    Sentiment: Strong Buy

  • If you want to keep your CLDX shares, don't place a trailing stop order.

    IOs want as many of your shares as they can shake loose.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Jan 27, 2015 7:43 PM Flag

    Oh, and the cup and handle formation is complete and showing signs of an imminent breakout higher. That will attract the attention and buying interest of technical traders and momentum traders.

    Sentiment: Strong Buy

  • Apple's strong earnings should assist the market in rebounding tomorrow from today's selloff.

    Additionally, as another poster observed, the Varli/Nivo combination trials are now listed as recruiting on the clinical trials website. There ought to be a press release announcing that fact before market open tomorrow.

    A rebounding market with a press release about a potentially effective and lucrative combination immunotherapy treatment ought to give CLDX shares strong support, perhaps enough to run up to $25 and test that level.

    Combine all the above with the news today about the short interest in CLDX increasing to 20 million shares, and there is the potential for a mini short squeeze if CLDX is able to breach $25 and convince shorts to begin covering their losing positions.

    Sentiment: Strong Buy

YHOO
44.13-0.31(-0.69%)Apr 1 4:00 PMEDT